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Abstract 
PIP4K2A is a lipid kinase that phosphorylates 
phosphatidylinositol (PtdIns) 5P, generating 
PtdIns4,5P2, which is an important precursor to 
second messengers of the phosphoinositide signal 
transduction pathways. Recently, studies have 
indicated that PIP4K2A is involved in the regulation 
of important biological processes that participate in 
the malignant phenotype, including cell 
proliferation, clonogenicity and survival. The 
present review on PIP4K2A contains data on 
DNA/RNA, protein encoded and where the gene is 
implicated. 
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Identity 
Other names: PIPK, PI5P4KA, PIP5K2A, 
PIP5KIIA, PIP5KII-alpha 
HGNC (Hugo): PIP4K2A 
Location: 10p12.2 
DNA/RNA 
Description 
The entire PIP4K2A gene is about 179.7 Kb (start: 
22534837 and end: 22714574 bp; orientation: Minus 
strand) and contains 10 exons.  
The PIP4K2A cDNA contains 3.8 Kb. 
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Protein 
Description 
PIP4K2A protein consists of 406 aminoacids with a 
molecular weight of 53 kDa and has a conserved 
phosphatidylinositol phosphate kinase (PIPK) 
domain in the C-terminal region. The schematic 
representation of PIP4K2A protein is illustrated in 
Figure 1. 
Expression 
Ubiquitous. 
Localisation 
PIP4K2A is predominantly located in the cytoplasm. 
However, in some cell types PIP4K2A was found in 
both nucleus and cytoplasm (Figure 2). 
Function 
PIP4K2A belongs to the class II of the  
phosphatidylinositol-5-phosphate 4-kinase family, 
and major function of these proteins is to recognize 
the phosphatidylinositol (PtdIns) phosphorylated at 
position five (PtdIns5P) and phosphorylate inositol 
ring in position four, to generate a new lipid 
messenger, the phosphatidylinositol-4,5-
bisphosphate (PtdIns4,5P2) (Figure 3).  
The PtdIns4,5P2 plays an important role in 
phosphoinositide signaling, participating in several 
cell processes, including vesicle transport, cell 
proliferation, adhesion, apoptosis and nuclear events 
(revised in McCrea and De Camilli, 2009). The 
acknowledgment about the functions of PIP4K 
proteins in cellular mechanism is still under 
construction and recent findings suggest that this 
protein family is strongly involved in oxidative 
stress and cellular senescence (revised in Fiume, et 
al., 2015).  
In contrast, the specific functions of PIP4K2A are 
poorly elucidated, and seems to vary according to 
cell type and stimulus.  
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Table 1. Comparative identity of human PIP4K2A with other species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
 
For instance, PIP4K2A silencing reduces cell 
survival in THP1 cells (an acute myeloid leukemia 
cells) (Jude, et al., 2015), but not in K562 cells (a 
chronic myeloid leukemia cell line) (Peretti de 
Albuquerque Wobeto, et al., 2014), whereas its 
overexpression reduces clonogenicity and sensibility 
to oxidative stress in O2OS cells (Jones, et al., 2013).  
PIP4K2A was initially identified in erythrocytes 
(Ling, et al., 1989) and its expression was found to 
be upregulated during erythroid differentiation 
(Peretti de Albuquerque Wobeto, et al., 2014, 
Zaccariotto, et al., 2012), suggesting a potential 
participation in cell differentiation.  
Of note, among the PIP4K proteins, which include 
PIP4K2A, PIP4K2B and PIP4KC, PIP4K2A has 
been reported as having the highest kinase activity 
(Bultsma, et al., 2010).  
PIP4K2A might also form heterodimer with 
PIP4K2B and result in PIP4K2A nuclear 
translocation (Bultsma, et al., 2010, Wang, et al., 
2010). 
Homology 
PIP4K2A shares high homology with the other 
members of the PIP4K protein family, including 
PIP4K2B and PIP4K2C. PIP4K2A also shares high 
homology among different species (Table 1). 
 
Mutations 
Somatic 
Recurrent mutations in the PIP4K2A gene are rare, 
68 substitution missense, 1 substitution nonsense, 19 
substitution synonymous, 2 insertion frameshift and 
4 deletion frameshift mutations are reported in 
COSMIC (Catalogue of somatic mutations in cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). 
Implicated in 
Acute Leukemia 
Wobeto and colleagues (Peretti de Albuquerque 
Wobeto, et al., 2014) reported that PIP4K2A is a 
nuclear and cytoplasm protein widely expressed in 
myeloid leukemia cell lines, and that PIP4K2A 
inhibition induces hemoglobin production and 
slightly decreases cell proliferation, but does not 
modulate apoptosis in K562 cells. Using a targeted 
knockdown screen for phosphoinositide modulator 
genes as approach, Jude and colleagues (Jude, et al., 
2015) identified PIP4K2A as an important gene for 
proliferation, clonogenicity and survival of acute 
myeloid leukemia cells. In this work, the sensibility  
 
to PIP4K2A inhibition was modulated by CDKN1A 
(p21) and mTOR activation. Szczepanek and 
colleagues (Szczepanek, et al., 2012), using ex vivo 
drug sensitivity experiments and DNA microarray 
analysis in childhood acute lymphoblastic leukemia 
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cells, found that PIP4K2A gene signature was 
associated with drug resistance for vincristine, 
thioguanine, melphalan and doxorubicin.  
Recently, our research group (Lima, et al., 2015) 
observed that PIP4K2A expression was reduced in a 
panel of myeloid and lymphoid leukemia cells when 
compared with normal leukocytes.  
Similar PIP4K2A expression prolife was observed in 
acute lymphoblastic leukemia patients compared 
with healthy donors.  
In our study, HEL cells, a myeloid leukemia cell line 
that presents very low levels of p21, and Namalwa 
cells, a lymphoid leukemia cell line, that presents 
constitutive PI3K/AKT activation, did not show any 
modulation regarding cell proliferation, 
clonogenicity and apoptosis upon PIP4K2A 
silencing (Lima, et al., 2015). 
Myelodysplastic syndromes 
In a cohort of 54 untreated patients with 
myelodysplastic syndromes (MDS) was observed a 
reduction of PIP4K2A expression in ≥5% bone 
marrow blats MDS patients group and an association 
between low expression of PIP4K2A and high blast 
percentage.  
Interestingly, MDS patients with low levels of 
PIP4K2A (stratified by tertiles) presented reduced 
overall survival by univariate analysis (Lima, et al., 
2015). 
Breast cancer 
Emerling and colleagues (Emerling, et al., 2013), 
using immunohistochemistry and western blot, 
reported that PIP4K2A is highly expressed in 
primary samples and cell lines from breast cancer. In 
this study, PIP4K2A plus PIP4K2B silencing 
reduced cell proliferation and tumor growth and 
induced cell senescence of  null, but not of p53 wild 
type, breast cancer cell lines.  
Of note that triple knockout mice for PIP4K2A, 
PIP4K2B and TP53 presented reduced tumor burden 
and increased tumor free survival compared with 
Tp53 knockout mice (Emerling, et al., 2013). 
Osteosarcoma 
Using the osteosarcoma cell line, U2OS cells, Jones 
and colleagues (Jones, et al., 2013) observed that 
induction of oxidative stress inhibits PIP4K2A 
activity and PIP4K2A overexpression reduces 
clonogenic cell growth.  
In contrast, PIP4K2A overexpression increased cell 
viability in response to oxidative stress in U2OS 
cells (Jones, et al., 2013). 
To be noted 
PIP4K2A knockout has been reported in several 
organisms, including fly, worm, fish and mouse, and 
different phenotypes has been described. In 
Drosophila and zebrafish, PIP4K2A orthologue 
protein knockout resulted in strong defective 
development (Gupta, et al., 2013, Elouarrat, et al., 
2013). In Caenorhabditis elegans, PIP4K2A 
orthologue protein knockout did not lead to 
developmental defects, but increased oxidative stress 
(Fiume, et al., 2015). In mice, Pip4k2a knockout did 
not present any aberrant phenotype (Emerling, et al., 
2013). 
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